
|Articles|April 14, 2008
Novartis to buy 25% of Alcon
Novartis is to purchase 25% of Alcon from majority stakeholder Nestlé, with an option to purchase Nestlé's remaining shares, which currently amount to approximately 52% of Alcon.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Macular laser picks up speed: The technology accelerating retinal therapies
2
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
3
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
4
FLORetina 2025: Enrico Borrelli on reframing retinal disease through the lens of choroidal health
5













































